Does the media refer more to IRWD or ABBV?

In the previous week, AbbVie had 57 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 58 mentions for AbbVie and 1 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 0.72 beat Ironwood Pharmaceuticals' score of 0.50 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 24 Very Positive mention(s) 12 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor IRWD or BEAM?

In the previous week, Beam Therapeutics had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Beam Therapeutics and 1 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.50 beat Beam Therapeutics' score of 0.30 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IRWD or IRON?

In the previous week, Disc Medicine had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 2 mentions for Disc Medicine and 1 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.50 beat Disc Medicine's score of 0.41 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMNM or IRWD?

In the previous week, Immunome had 9 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 10 mentions for Immunome and 1 mentions for Ironwood Pharmaceuticals. Immunome's average media sentiment score of 0.62 beat Ironwood Pharmaceuticals' score of 0.50 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 6 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRWD or CLDX?

In the previous week, Celldex Therapeutics had 4 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for Celldex Therapeutics and 1 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.50 beat Celldex Therapeutics' score of 0.15 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ironwood Pharmaceuticals (IRWD) Competitors

$3.64 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.67 +0.03 (+0.85%)

As of 05:01 AM Eastern

Compare

IRWD vs. ABBV, BEAM, IRON, IMNM, and CLDX

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? Ironwood Pharmaceuticals's main competitors and comparable companies include AbbVie (ABBV), Beam Therapeutics (BEAM), Disc Medicine (IRON), Immunome (IMNM), and Celldex Therapeutics (CLDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ironwood Pharmaceuticals compare to AbbVie?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

70.2% of AbbVie shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ironwood Pharmaceuticals has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

In the previous week, AbbVie had 57 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 58 mentions for AbbVie and 1 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 0.72 beat Ironwood Pharmaceuticals' score of 0.50 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	24 Very Positive mention(s)	12 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a net margin of 33.36% compared to AbbVie's net margin of 9.80%. Ironwood Pharmaceuticals' return on equity of -58.38% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
AbbVie	9.80%	-422.07%	14.34%

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, indicating a potential upside of 71.25%. AbbVie has a consensus target price of $272.39, indicating a potential upside of 3.47%. Given Ironwood Pharmaceuticals' higher probable upside, research analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	2.87

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.03	$24.02M	$0.77	4.73
AbbVie	$61.16B	7.61	$4.23B	$3.54	74.37

Summary

AbbVie beats Ironwood Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, suggesting a potential upside of 71.25%. Beam Therapeutics has a consensus price target of $49.00, suggesting a potential upside of 100.00%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Ironwood Pharmaceuticals has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.03	$24.02M	$0.77	4.73
Beam Therapeutics	$139.74M	18.11	-$79.99M	-$0.86	N/A

99.7% of Beam Therapeutics shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market.

In the previous week, Beam Therapeutics had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Beam Therapeutics and 1 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.50 beat Beam Therapeutics' score of 0.30 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ironwood Pharmaceuticals and Beam Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Disc Medicine?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, indicating a potential upside of 71.25%. Disc Medicine has a consensus target price of $110.18, indicating a potential upside of 70.80%. Given Ironwood Pharmaceuticals' higher probable upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

83.7% of Disc Medicine shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Disc Medicine had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 2 mentions for Disc Medicine and 1 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.50 beat Disc Medicine's score of 0.41 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Disc Medicine's net margin of 0.00%. Disc Medicine's return on equity of -37.17% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Disc Medicine	N/A	-37.17%	-33.65%

Ironwood Pharmaceuticals has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.03	$24.02M	$0.77	4.73
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Summary

Ironwood Pharmaceuticals beats Disc Medicine on 10 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Immunome?

Immunome (NASDAQ:IMNM) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Immunome presently has a consensus target price of $34.25, indicating a potential upside of 63.88%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 71.25%. Given Ironwood Pharmaceuticals' higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Ironwood Pharmaceuticals has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	342.05	-$212.39M	-$2.53	N/A
Ironwood Pharmaceuticals	$296.15M	2.03	$24.02M	$0.77	4.73

In the previous week, Immunome had 9 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 10 mentions for Immunome and 1 mentions for Ironwood Pharmaceuticals. Immunome's average media sentiment score of 0.62 beat Ironwood Pharmaceuticals' score of 0.50 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	6 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

44.6% of Immunome shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Immunome has a beta of 2.55, indicating that its share price is 155% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Immunome's net margin of 0.00%. Immunome's return on equity of -50.56% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Summary

Ironwood Pharmaceuticals beats Immunome on 9 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Celldex Therapeutics?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

In the previous week, Celldex Therapeutics had 4 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for Celldex Therapeutics and 1 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.50 beat Celldex Therapeutics' score of 0.15 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Celldex Therapeutics' net margin of 0.00%. Celldex Therapeutics' return on equity of -52.35% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Ironwood Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.03	$24.02M	$0.77	4.73
Celldex Therapeutics	$1.54M	1,613.94	-$258.76M	-$4.35	N/A

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, suggesting a potential upside of 71.25%. Celldex Therapeutics has a consensus price target of $61.92, suggesting a potential upside of 95.65%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Ironwood Pharmaceuticals has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Ironwood Pharmaceuticals and Celldex Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRWD vs. The Competition

Export

Metric	Ironwood Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$601.47M	$3.85B	$7.13B	$13.26B
Dividend Yield	N/A	3.65%	2.53%	17.33%
P/E Ratio	4.73	13.06	275.01	26.04
Price / Sales	2.03	1,291.93	609.11	91.95
Price / Cash	14.14	39.04	27.22	34.69
Price / Book	-2.26	16.86	11.06	6.34
Net Income	$24.02M	-$23.20M	$3.50B	$381.61M
7 Day Performance	-11.65%	-2.84%	-1.85%	-0.72%
1 Month Performance	-14.55%	-10.81%	-6.23%	-4.68%
1 Year Performance	134.84%	18.93%	7.99%	1.57%

Ironwood Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRWD Ironwood Pharmaceuticals	2.3816 of 5 stars	$3.64 flat	$6.23 +71.2%	+134.8%	$601.47M	$296.15M	4.73	100
ABBV AbbVie	4.0496 of 5 stars	$265.01 -0.5%	$272.66 +2.9%	+12.5%	$470.40B	$61.16B	75.21	57,000	Trending News
BEAM Beam Therapeutics	2.3941 of 5 stars	$24.15 -0.3%	$49.00 +102.9%	-4.9%	$2.50B	$139.74M	N/A	540	Analyst Upgrade Gap Up
IRON Disc Medicine	2.5286 of 5 stars	$64.87 -0.1%	$110.18 +69.9%	-4.8%	$2.48B	N/A	N/A	165
IMNM Immunome	2.8397 of 5 stars	$21.74 +0.3%	$35.18 +61.8%	+68.8%	$2.47B	$6.94M	N/A	177	Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRWD) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BEAM, IRON, IMNM, and CLDX

How does Ironwood Pharmaceuticals compare to AbbVie?

Summary

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Summary

How does Ironwood Pharmaceuticals compare to Disc Medicine?

Summary

How does Ironwood Pharmaceuticals compare to Immunome?

Summary

How does Ironwood Pharmaceuticals compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BEAM, IRON, IMNM, and CLDX

How does Ironwood Pharmaceuticals compare to AbbVie?

Do insiders & institutionals hold more shares of IRWD or ABBV?

Which has more volatility & risk, IRWD or ABBV?

Does the media refer more to IRWD or ABBV?

Is IRWD or ABBV more profitable?

Do analysts rate IRWD or ABBV?

Which has higher earnings & valuation, IRWD or ABBV?

Summary

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Is IRWD or BEAM more profitable?

Do analysts prefer IRWD or BEAM?

Which has preferable earnings and valuation, IRWD or BEAM?

Do insiders and institutionals have more ownership in IRWD or BEAM?

Which has more volatility & risk, IRWD or BEAM?

Does the media favor IRWD or BEAM?

Summary

How does Ironwood Pharmaceuticals compare to Disc Medicine?

Do analysts prefer IRWD or IRON?

Do institutionals & insiders hold more shares of IRWD or IRON?

Does the media refer more to IRWD or IRON?

Is IRWD or IRON more profitable?

Which has more risk and volatility, IRWD or IRON?

Which has preferable earnings & valuation, IRWD or IRON?

Summary

How does Ironwood Pharmaceuticals compare to Immunome?

Do analysts recommend IMNM or IRWD?

Which has higher valuation & earnings, IMNM or IRWD?

Does the media prefer IMNM or IRWD?

Do insiders and institutionals believe in IMNM or IRWD?

Which has more risk and volatility, IMNM or IRWD?

Is IMNM or IRWD more profitable?

Summary

How does Ironwood Pharmaceuticals compare to Celldex Therapeutics?

Does the media prefer IRWD or CLDX?

Is IRWD or CLDX more profitable?

Which has higher earnings and valuation, IRWD or CLDX?

Do analysts prefer IRWD or CLDX?

Which has more risk & volatility, IRWD or CLDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools